Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Alamar Biosciences, Inc. President Timothy Ogden White filed an initial ownership report showing direct holdings of 454,583 shares of Class B Common Stock. He also reports multiple stock options to buy Class B Common Stock, with exercise prices ranging from $0.59 to $7.60 per share and expirations between 2031 and 2036, many vesting in equal monthly installments over 48 months, subject to his continuous service.
Alamar Biosciences, Inc. Chief Executive Officer Luo Yuling filed an initial statement of beneficial ownership, listing existing share and option positions as of April 16, 2026. The filing shows direct and indirect holdings of Class A and Class B Common Stock, preferred stock, and multiple vested and time-vesting stock options.
Alamar Biosciences, Inc. is conducting an initial public offering of 9,375,000 shares of common stock, with an expected price range of $15.00 to $17.00 per share, and has granted underwriters a 30-day option to buy up to 1,406,250 additional shares.
The company seeks to list on the Nasdaq Global Select Market under the symbol “ALMR.” Alamar is a commercial-stage proteomics company built around its proprietary NULISA technology and ARGO HT instruments, targeting ultra-sensitive, multiplex protein detection for research and future diagnostics.
Revenue grew from $25.1 million in 2024 to $74.2 million in 2025, a 195% increase, while gross margin improved from 34% to 56%. The company remains unprofitable, with net losses of $47.1 million in 2024 and $29.8 million in 2025, and expects Q1 2026 revenue between $25.2 million and $26.2 million.